- Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) hyperimmune globulin mimic developed with Biohaven's MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains found in the U.K and South Africa (B.1.1.7 and B.1.351, respectively).
- Preliminary lab experiments demonstrated that BHV-1200 substantially reduced viral entry into cells.
- The Bill and Melinda Gates Foundation supports the development of the COVID-19 MATE program.
- Besides, the in vitro data indicate that BHV-1200 may activate important immune system components.
- Price Action: BHVN is down 2.29% at $80.99 in market trading hours on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in